Akihiro Sakurai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akihiro Sakurai has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Nakase
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
4 shared publications- Masashi Idogawa
Division of Medical Genome Sciences, Department of Genomic and Preventive Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
4 shared publications Tsuyoshi Saito
Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan
4 shared publicationsTakashi Tokino
Department of Medical Genome Sciences, Cancer Research Institute, Sapporo Medical University School of Medicine, Sapporo, Japan
2 shared publicationsTasuku Mariya
Division of Clinical Genomics, Department of Genomic and Preventive Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
2 shared publications- Tasuku Mariya
Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Varporter: a software platform for comprehensive genomic profiling (CGP) in cancer
The use of comprehensive genomic profiling (CGP) in cancer, also known as cancer gene panel tests, continues to expand; however, the interpretation of the results of these tests requires a tremendous amount of manual work. To improve the efficiency of this evaluation process, we developed the CGP support software named Varporter. This software automatically imports multiple data files and can display various information contained within the CGP results. In tumor-only tests, TP53 variants often require pathogenicity evaluation as presumed germline pathogenic variants. Varporter enables the automated determination of several criteria in the Variant Interpretation Guidelines established by the ClinGen TP53 Variant Curation Expert Panel. Direct links to the websites on therapeutic evidence are also automatically generated from each variant, and multiple test reports can be summarized onto a single sheet, thus making it easy to review newly added variants to clinical trials. Varporter has made it possible to automate and streamline complicated manual tasks related to CGP evaluation and to redirect human resources to more essential tasks. Varporter is designed for use with two CGP tests covered by Japanese national health insurance, FoundationOne CDx and Guardant360 CDx.
- 24 July 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Open AccessVarporter: a software platform for comprehensive genomic profiling (CGP) in cancer
The use of comprehensive genomic profiling (CGP) in cancer, also known as cancer gene panel tests, continues to expand; however, the interpretation of the results of these tests requires a tremendous amount of manual work. To improve the efficiency of this evaluation process, we developed the CGP support software named Varporter. This software automatically imports multiple data files and can display various information contained within the CGP results. In tumor-only tests, TP53 variants often require pathogenicity evaluation as presumed germline pathogenic variants. Varporter enables the automated determination of several criteria in the Variant Interpretation Guidelines established by the ClinGen TP53 Variant Curation Expert Panel. Direct links to the websites on therapeutic evidence are also automatically generated from each variant, and multiple test reports can be summarized onto a single sheet, thus making it easy to review newly added variants to clinical trials. Varporter has made it possible to automate and streamline complicated manual tasks related to CGP evaluation and to redirect human resources to more essential tasks. Varporter is designed for use with two CGP tests covered by Japanese national health insurance, FoundationOne CDx and Guardant360 CDx.
- Open Access
- 21 January 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Updated analysis of pathogenic variants in BRCA1/BRCA2 among the general Japanese population
Recently, the Tohoku Medical Megabank Organization released whole-genome allele frequencies of single-nucleotide variants and indels from approximately 60,000 individuals from the general Japanese population in the Tohoku region (60KJPN). Here we analyzed the 60KJPN dataset for BRCA1 / BRCA2 variants and compared them with the previous version, 54KJPN, to ascertain the frequency of hereditary breast and ovarian cancers in the general Japanese population. We hope that these results will contribute to strategies for cancer prevention.
- 21 January 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Open AccessUpdated analysis of pathogenic variants in BRCA1/BRCA2 among the general Japanese population
Recently, the Tohoku Medical Megabank Organization released whole-genome allele frequencies of single-nucleotide variants and indels from approximately 60,000 individuals from the general Japanese population in the Tohoku region (60KJPN). Here we analyzed the 60KJPN dataset for BRCA1 / BRCA2 variants and compared them with the previous version, 54KJPN, to ascertain the frequency of hereditary breast and ovarian cancers in the general Japanese population. We hope that these results will contribute to strategies for cancer prevention.
- Open Access
- 14 March 2024
- Published by Springer Nature in Journal of Human Genetics
- Vol. 69 (5) , 231-234
Correction: The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population
- 14 March 2024
- Published by Springer Nature in Journal of Human Genetics
- Vol. 69 (5) , 231-234
Open AccessCorrection: The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population
- 27 February 2024
- Published by Springer Nature in Journal of Human Genetics
- Vol. 69 (5) , 225-230
The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population
Hereditary breast and ovarian cancer syndrome (HBOC) resulting from pathogenic variants of BRCA1 or BRCA2 is the most common and well-documented hereditary tumor. Although founder variants have been identified in population-based surveys in various countries, the types of variants are not uniform across races and regions. Recently, the Tohoku Medical Megabank Organization (ToMMo) released whole-genome sequence data including approximately 54,000 individuals from the general population of the Tohoku area in Japan. We analyzed these data and comprehensively identified the prevalence of BRCA1/2 pathogenic and truncating variants. We believe that an accurate understanding of the unique distribution and characteristics of pathogenic BRCA1/2 variants in Japan through this analysis will enable better surveillance and intervention for HBOC patients, not only in Japan but also worldwide.
- 27 February 2024
- Published by Springer Nature in Journal of Human Genetics
- Vol. 69 (5) , 225-230
The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population
Hereditary breast and ovarian cancer syndrome (HBOC) resulting from pathogenic variants of BRCA1 or BRCA2 is the most common and well-documented hereditary tumor. Although founder variants have been identified in population-based surveys in various countries, the types of variants are not uniform across races and regions. Recently, the Tohoku Medical Megabank Organization (ToMMo) released whole-genome sequence data including approximately 54,000 individuals from the general population of the Tohoku area in Japan. We analyzed these data and comprehensively identified the prevalence of BRCA1/2 pathogenic and truncating variants. We believe that an accurate understanding of the unique distribution and characteristics of pathogenic BRCA1/2 variants in Japan through this analysis will enable better surveillance and intervention for HBOC patients, not only in Japan but also worldwide.
- Open Access
- 3 October 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (1) , 47-53
Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study
Accumulating evidence has demonstrated platinum-based chemotherapy followed by maintenance therapy with a poly Adenosine diphosphate (ADP)-ribose polymerase inhibitor (olaparib) show benefits in unresectable pancreatic cancer with a germline (g)BRCA1/2 mutation. Evaluation of the germline BRCA1 and BRCA2 mutation is essential for making decisions on a treatment strategy for patients with unresectable pancreatic cancer. However, the detection rates of germline BRCA1 and BRCA2 mutations and efficacy of maintenance with olaparib remain undetermined, prospectively, in Japan. In this prospective analysis, the rate of germline BRCA1 and BRCA2 mutations and efficacy of chemotherapy were analyzed in 136 patients with pancreatic cancer who underwent BRACAnalysis® (85 patients) or FoundationOne® CDx (51 patients) between January 2020 and July 2022. A total of six patients (4.4%) had a germline BRCA1 and BRCA2 mutation. Five patients were treated with modified FOLFIRINOX and one with fluorouracil and oxaliplatin. All patients continued platinum-based chemotherapy for ˃4 months and were subsequently treated with olaparib as a maintenance therapy. The response rate to platinum-based chemotherapy in the germline BRCA1 and BRCA2 mutation-positive group was significantly better than that of the germline BRCA1 and BRCA2 mutation-negative group (66% vs 23%, P = 0.04). All patients harbouring a germline BRCA1 and BRCA2 mutation were able to switch to olaparib. The median progression-free survival using olaparib was 5.7 months (range 3.0–9.2). The rate of germline BRCA1 and BRCA2 mutations found in patients with unresectable pancreatic cancer was comparable to those of previous studies. An analysis of germline BRCA1 and BRCA2 mutations has benefits for all patients with unresectable pancreatic cancer with regard to decisions on therapeutic strategies in a clinical practice setting.
- 3 October 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (1) , 47-53
Open AccessClinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study
Accumulating evidence has demonstrated platinum-based chemotherapy followed by maintenance therapy with a poly Adenosine diphosphate (ADP)-ribose polymerase inhibitor (olaparib) show benefits in unresectable pancreatic cancer with a germline (g)BRCA1/2 mutation. Evaluation of the germline BRCA1 and BRCA2 mutation is essential for making decisions on a treatment strategy for patients with unresectable pancreatic cancer. However, the detection rates of germline BRCA1 and BRCA2 mutations and efficacy of maintenance with olaparib remain undetermined, prospectively, in Japan. In this prospective analysis, the rate of germline BRCA1 and BRCA2 mutations and efficacy of chemotherapy were analyzed in 136 patients with pancreatic cancer who underwent BRACAnalysis® (85 patients) or FoundationOne® CDx (51 patients) between January 2020 and July 2022. A total of six patients (4.4%) had a germline BRCA1 and BRCA2 mutation. Five patients were treated with modified FOLFIRINOX and one with fluorouracil and oxaliplatin. All patients continued platinum-based chemotherapy for ˃4 months and were subsequently treated with olaparib as a maintenance therapy. The response rate to platinum-based chemotherapy in the germline BRCA1 and BRCA2 mutation-positive group was significantly better than that of the germline BRCA1 and BRCA2 mutation-negative group (66% vs 23%, P = 0.04). All patients harbouring a germline BRCA1 and BRCA2 mutation were able to switch to olaparib. The median progression-free survival using olaparib was 5.7 months (range 3.0–9.2). The rate of germline BRCA1 and BRCA2 mutations found in patients with unresectable pancreatic cancer was comparable to those of previous studies. An analysis of germline BRCA1 and BRCA2 mutations has benefits for all patients with unresectable pancreatic cancer with regard to decisions on therapeutic strategies in a clinical practice setting.
- 31 May 2022
- Published by Springer Nature in Breast Cancer
- Vol. 29 (5) , 808-813
Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer
Background When considering BRCA1/2 genetic testing for diagnosis of hereditary breast and ovarian cancer (HBOC), family history (FH) of breast and ovarian cancer is commonly considered. However, FH of other HBOC-related cancers, such as prostate, pancreatic, and skin cancer (malignant melanoma), is often overlooked. Methods Among 945 patients who received genetic testing of BRCA1/2 at our hospital between October 2010 and September 2021, we compared the FH of 123 patients diagnosed with HBOC and 669 other patients who had breast cancer and had a documented FH. This study focused on the FH of HBOC-related cancers such as breast, ovarian, prostate, pancreatic, and skin cancer, as well as colorectal, gastric, liver, lung, and uterine cancers, which are common among Japanese, and other cancers. Results FH of prostate, pancreatic, and skin cancer was significantly higher in the BRCA2 pathogenic variant (PV) cases than in the wild-type (WT) cases. The mean number of family members are as follows: BRCA1 PV/ BRCA2 PV/ WT; prostate cancer: 0.05/ 0.34/ 0.09 (P < 0.0001, Kruskal–Wallis multiple comparisons test), pancreatic cancer: 0.13/ 0.21/ 0.10 (P = 0.01637), and skin cancer: 0.03/ 0.07/ 0.01 (P = 0.00129), respectively. Conclusions When considering BRCA1/2 genetic testing, FH of prostate, pancreatic, and skin cancers may also be examined as HBOC-related cancers to provide testing for patients who would benefit from it. However, further studies for the association between skin cancer and HBOC will be required because it has not been reported in Japan.
- 31 May 2022
- Published by Springer Nature in Breast Cancer
- Vol. 29 (5) , 808-813
Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer
Background When considering BRCA1/2 genetic testing for diagnosis of hereditary breast and ovarian cancer (HBOC), family history (FH) of breast and ovarian cancer is commonly considered. However, FH of other HBOC-related cancers, such as prostate, pancreatic, and skin cancer (malignant melanoma), is often overlooked. Methods Among 945 patients who received genetic testing of BRCA1/2 at our hospital between October 2010 and September 2021, we compared the FH of 123 patients diagnosed with HBOC and 669 other patients who had breast cancer and had a documented FH. This study focused on the FH of HBOC-related cancers such as breast, ovarian, prostate, pancreatic, and skin cancer, as well as colorectal, gastric, liver, lung, and uterine cancers, which are common among Japanese, and other cancers. Results FH of prostate, pancreatic, and skin cancer was significantly higher in the BRCA2 pathogenic variant (PV) cases than in the wild-type (WT) cases. The mean number of family members are as follows: BRCA1 PV/ BRCA2 PV/ WT; prostate cancer: 0.05/ 0.34/ 0.09 (P < 0.0001, Kruskal–Wallis multiple comparisons test), pancreatic cancer: 0.13/ 0.21/ 0.10 (P = 0.01637), and skin cancer: 0.03/ 0.07/ 0.01 (P = 0.00129), respectively. Conclusions When considering BRCA1/2 genetic testing, FH of prostate, pancreatic, and skin cancers may also be examined as HBOC-related cancers to provide testing for patients who would benefit from it. However, further studies for the association between skin cancer and HBOC will be required because it has not been reported in Japan.
- Open Access
- 10 July 2021
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 110 (7) , 1502-1508
Recent Advances in Gastroenteropancreatic Neuroendocrine Neoplasms
膵・消化管の神経内分泌腫瘍(neuroendocrine neoplasm:NEN)は頻度の低い疾患ではあるが,その頻度は年々増加しており,日本人の疫学データも蓄積されつつある.診断については正確な病理診断が極めて重要であり,治療方針の根拠ともなるが,WHO(World Health Organization)の病理学的分類が最近改訂され,また,腫瘍自体の名称も,それまでのneuroendocrine tumor(NET)からNENに統一された.ただし,病理分類ではNETという用語が用いられている.また,近年のゲノム解析技術の進展により,NENでも精力的な解析が行われ,NETとNEC(neuroendocrine carcinoma)は別の発生機序に基づくことが明らかにされた.我が国でもNENに使用できる薬剤はここ数年間で増加し,さらにまもなく核医学治療も導入される予定で,治療の選択肢が広がりつつある.
- 10 July 2021
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 110 (7) , 1502-1508
Open AccessRecent Advances in Gastroenteropancreatic Neuroendocrine Neoplasms
膵・消化管の神経内分泌腫瘍(neuroendocrine neoplasm:NEN)は頻度の低い疾患ではあるが,その頻度は年々増加しており,日本人の疫学データも蓄積されつつある.診断については正確な病理診断が極めて重要であり,治療方針の根拠ともなるが,WHO(World Health Organization)の病理学的分類が最近改訂され,また,腫瘍自体の名称も,それまでのneuroendocrine tumor(NET)からNENに統一された.ただし,病理分類ではNETという用語が用いられている.また,近年のゲノム解析技術の進展により,NENでも精力的な解析が行われ,NETとNEC(neuroendocrine carcinoma)は別の発生機序に基づくことが明らかにされた.我が国でもNENに使用できる薬剤はここ数年間で増加し,さらにまもなく核医学治療も導入される予定で,治療の選択肢が広がりつつある.
- 1 January 2019
- Published by Japan Society of Mechanical Engineers in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
- Vol. 2019, 1P1-R04
Development of Sport Training Method Interveneing by Sound Information Generated from Results of Motion Analysis
Kinematic sequence of golf swing is the order of events which is characteristic motion of body parts measured by its speed or angular velocity and so on. If the shots are ideal, the orders of kinematic sequence are all the same sequence. Kinematic sequence gotten from the golf swing is expected to be useful to improve them. To propose effective auditory interactive training, we used kinematic sequence and top speed information gotten from the golf swing. By experiments with proposed method, we showed kinematic sequence order improvement by proposed training method on intermediate subject.
- 1 January 2019
- Published by Japan Society of Mechanical Engineers in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
- Vol. 2019, 1P1-R04
Development of Sport Training Method Interveneing by Sound Information Generated from Results of Motion Analysis
Kinematic sequence of golf swing is the order of events which is characteristic motion of body parts measured by its speed or angular velocity and so on. If the shots are ideal, the orders of kinematic sequence are all the same sequence. Kinematic sequence gotten from the golf swing is expected to be useful to improve them. To propose effective auditory interactive training, we used kinematic sequence and top speed information gotten from the golf swing. By experiments with proposed method, we showed kinematic sequence order improvement by proposed training method on intermediate subject.
- 1 January 2017
- Published by JLE in European Journal Of Dermatology
- Vol. 27 (1) , 54-58
Muir-Torre syndrome caused by exonic deletion of MLH1 due to homologous recombination
Muir-Torre syndrome (MTS) is characterized by sebaceous neoplasms with internal malignancies and regarded as a variant of hereditary nonpolyposis colorectal cancer (HNPCC). Pathogenic variations of MTS have been identified in the MSH2, MLH1, and MSH6 genes, with the majority of variations located in MSH2. To present an MTS patient who was the only individual with skin malignancies within a cancer-prone pedigree and to show the usefulness of RNA-based genetic analysis in the investigation of MTS. A 77-year-old man who had operated X-ray equipment at his workplace in his twenties was clinically diagnosed with MTS and investigated by RNA-based analysis, multiplex ligation-dependent probe amplification, and genomic DNA sequencing. The patient had suffered from sebaceous tumours, squamous cell carcinomas of the skin, and colon cancer. The patient's family history was remarkable for visceral malignant diseases. Genetic analysis revealed homologous recombination between two Alu elements within intron 4 and 5 of the MLH1 gene. The rearrangement caused a 1,222-bp deletion, including the entire exon 5. Deletion of exon 5 has previously been reported only in two patients with HNPCC, and not in patients with MTS. For the genetic analysis of MTS, the possibility of rare copy number variations of MLH1, as well as MSH2 variations, should be considered. RNA-based screening using puromycin is recommended in order to identify such variations. It remains unclear why only the proband among the pedigree had skin malignancies, however, the skin carcinogenesis might have been related to occupational radiation exposure.
- 1 January 2017
- Published by JLE in European Journal Of Dermatology
- Vol. 27 (1) , 54-58
Muir-Torre syndrome caused by exonic deletion of MLH1 due to homologous recombination
Muir-Torre syndrome (MTS) is characterized by sebaceous neoplasms with internal malignancies and regarded as a variant of hereditary nonpolyposis colorectal cancer (HNPCC). Pathogenic variations of MTS have been identified in the MSH2, MLH1, and MSH6 genes, with the majority of variations located in MSH2. To present an MTS patient who was the only individual with skin malignancies within a cancer-prone pedigree and to show the usefulness of RNA-based genetic analysis in the investigation of MTS. A 77-year-old man who had operated X-ray equipment at his workplace in his twenties was clinically diagnosed with MTS and investigated by RNA-based analysis, multiplex ligation-dependent probe amplification, and genomic DNA sequencing. The patient had suffered from sebaceous tumours, squamous cell carcinomas of the skin, and colon cancer. The patient's family history was remarkable for visceral malignant diseases. Genetic analysis revealed homologous recombination between two Alu elements within intron 4 and 5 of the MLH1 gene. The rearrangement caused a 1,222-bp deletion, including the entire exon 5. Deletion of exon 5 has previously been reported only in two patients with HNPCC, and not in patients with MTS. For the genetic analysis of MTS, the possibility of rare copy number variations of MLH1, as well as MSH2 variations, should be considered. RNA-based screening using puromycin is recommended in order to identify such variations. It remains unclear why only the proband among the pedigree had skin malignancies, however, the skin carcinogenesis might have been related to occupational radiation exposure.
- Open Access
- 1 January 2004
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 51 (3) , 333-342
JunD-Menin Interaction Regulates c-Jun-mediated AP-1 Transactivation
The gene responsible for multiple endocrine neoplasia type 1, MEN1, encodes the 610-amino acid-protein, menin. Although menin has been reported to bind AP-1 transcription factor JunD and suppress its transcriptional activity, little is known about its molecular mechanisms and physiological role. To better understand the function of menin and its significance in tumorigenesis, we investigated the effect of wild-type and mutant menin proteins on AP-1 transactivation. In COS cells, wild-type menin suppressed JunD-mediated transactivation in a dose-dependent manner, while it augmented c-Jun-mediated transactivation also in a dose-dependent manner. These effects were lost or reduced in all menin mutants examined. Electrophoretic mobility shift assay using AP-1 binding elements as a probe revealed that menin does not affect binding of c-Jun to DNA. Coexpression of menin mutants did not affect the function of wild-type menin. Coexpression of JunD amino-terminal fragment abolished menin-mediated enhancement of c-Jun transactivation, suggesting that Menin-JunD interaction may negatively regulate the enhancing effect of menin on c-Jun-mediated transactivation in COS cells.
- 1 January 2004
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 51 (3) , 333-342
Open AccessJunD-Menin Interaction Regulates c-Jun-mediated AP-1 Transactivation
The gene responsible for multiple endocrine neoplasia type 1, MEN1, encodes the 610-amino acid-protein, menin. Although menin has been reported to bind AP-1 transcription factor JunD and suppress its transcriptional activity, little is known about its molecular mechanisms and physiological role. To better understand the function of menin and its significance in tumorigenesis, we investigated the effect of wild-type and mutant menin proteins on AP-1 transactivation. In COS cells, wild-type menin suppressed JunD-mediated transactivation in a dose-dependent manner, while it augmented c-Jun-mediated transactivation also in a dose-dependent manner. These effects were lost or reduced in all menin mutants examined. Electrophoretic mobility shift assay using AP-1 binding elements as a probe revealed that menin does not affect binding of c-Jun to DNA. Coexpression of menin mutants did not affect the function of wild-type menin. Coexpression of JunD amino-terminal fragment abolished menin-mediated enhancement of c-Jun transactivation, suggesting that Menin-JunD interaction may negatively regulate the enhancing effect of menin on c-Jun-mediated transactivation in COS cells.